Changes to anti-JCV antibody levels in a Swedish national MS cohort

Clemens Warnke,1,2 Ryan Ramanujam,1 Tatiana Plavina,3 Tomas Bergström,4 Susan Goelz,5 Meena Subramanyam,3 Ingrid Kockum,1 Afsar Rahbar,6 Bernd C Kieseier,2 Carolina Holmén,1 Tomas Olsson,1 Jan Hillert,1 Anna Fogdell-Hahn1

ABSTRACT

Background The anti-JC virus (JCV) antibody status has been introduced to stratify patients with multiple sclerosis (MS) for higher or lower risk of progressive multifocal leukoencephalopathy (PML).

Objective To assess the potential utility of anti-JCV antibody levels for earlier diagnosis or prediction of PML.

Methods An analytically validated antibody assay was used to determine serological status, normalised optical density values, and dilution titres for anti-JCV antibodies. The method was applied to stored sera of 1157 patients with MS including five cases of PML, all enrolled in the Swedish pharmacovigilance study for natalizumab (NAT). Anti-lymphomatovirus/maculovirus (CMV) and antivaricella-zoster-virus (VZV) antibody levels served as controls.

Results Prior to treatment with NAT, anti-JCV antibody levels were stable in the anti-JCV positive patients. During therapy, a slight decrease in anti-JCV and anti-VZV antibody levels, but not anti-CMV antibody levels, was observed. All five patients who developed PML showed a mild to moderate increase in anti-JCV antibody levels at time of PML diagnosis; pre-PML samples suggested that this increase might start already prior to diagnosis of PML.

Conclusions Treatment initiation with NAT may lead to a slight decrease in anti-JCV and anti-VZV antibody levels, suggestive of a mild suppressive effect of NAT on antibody levels. Our findings in five cases of PML demonstrate that the onset of PML can be accompanied by increasing anti-JCV antibodies in serum. Monitoring of anti-JCV antibody levels at potential of PML during NAT treatment for MS. Further studies are warranted.

INTRODUCTION

Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). The transmigration of activated T cells from the peripheral blood into the CNS is considered as a crucial step to initiate and maintain this highly debilitating disease, a process in which the α4β1-integrin (VLA-4) is critically involved.1 Natalizumab (NAT) is a humanised monoclonal IgG4 antibody designed to specifically target this step in MS pathogenesis by blocking the α4-subunit of VLA-4 on activated T cells.2 Although clinically highly efficacious, the occurrence of cases of NAT-associated progressive multifocal leukoencephalopathy (PML), a CNS infection caused by the JC virus (JCV), limits its use.3–5 While many aspects of the pathogenesis of PML during NAT treatment still remain obscure, two elements have been recently elucidated: (a) sequencing analyses of the viral genome indicate that patients who develop PML have a pathogenic form of the virus, with specific changes in the regulatory region and the major viral capsid protein VP1 that may facilitate the spread of the virus from the periphery to the brain;6–8 (b) the inhibition of immune cell trafficking into the CNS by NAT could allow pathogenic forms of JCV to become established due to the reduced immune surveillance in the CNS.9 Consistent with these concepts, infection with JCV is considered a prerequisite for the development of PML. This assumption is supported by the observation that NAT-associated cases of PML tested positive for anti-JCV-IgG antibodies (anti-JCV antibodies) in samples taken prior to (range 6–187 months, n=64), or around the time of PML diagnosis (n=101).10–12 These findings have resulted in a two-step anti-JCV antibody assay being introduced to stratify patients with MS treated with NAT for lower or higher risk of PML.13–15

In Sweden, the patients with MS treated with NAT are included in a postmarketing surveillance study.16–17 A unique set of prospectively collected blood samples from this nationwide cohort allowed us to assess the potential utility of anti-JCV antibody levels in serum for earlier diagnosis or prediction of PML. For this purpose, anti-JCV antibody status and levels before and after treatment initiation with NAT were determined. The objective was to identify patients at higher or lower risk of developing PML. To this end, all patients enrolled in the Swedish pharmacovigilance study for NAT were included. The anti-JCV antibody status and levels before and after treatment initiation with NAT have been measured.

PATIENTS AND METHODS

Patients and samples

The study was performed within the Swedish postmarketing surveillance study for NAT.16–17 All patients gave written informed consent for this NAT-specific study, approved by the Karolinska Institutet regional ethical committee (KIDnr 2006/1:7, 2006-08-23). Until use, all samples were stored at −80°C. The initial NAT treatment for MS patients treated with NAT before March 2013. Downloaded from http://jnnp.bmj.com/ on March 7, 2022 by guest. Protected by copyright.
Multiple sclerosis (insufficient analysing quality, titres not done), or those previously treated with intravenous immunoglobulin were excluded from the study (total patients excluded: n=313); 844 patients remained including five patients with PML. For these patients (NAT-group, median time between sampling 12 months), a time point (t3) just before the first infusion with NAT was compared with a second measurement (t4) during NAT therapy. As illustrated in online supplementary efigure S1, antibody levels were also studied prior to NAT therapy during treatment with interferon beta (IFN) in a proportion of the same patients. Two subgroups were defined: for the largest, the IFN1-subgroup, samples at t1 and t3 were available, whereas the IFN2-subgroup had samples at an additional time point t2.

**Anti-JCV antibody detection and quantification**

A two-step assay to determine anti-JCV antibodies was applied to the samples as published before,10 performed at Focus Diagnostics (Cypress, CA, USA) and sponsored by Biogen Idec (Cambridge, Massachusetts, USA). Briefly, in the first step, the optical density (OD) was measured by ELISA, and samples with normalised OD (nOD) values above 0.25 were considered as positive, and below 0.1 as negative. For patients with nOD values between 0.1 and 0.25 (indeterminate zone), the percentage of inhibition was determined in a second step after precipitation with soluble JCV-like particle antigen. Samples with a percentage of inhibition >40% and a nOD range between 0.1 and 0.25 were deemed positive (indeterminate-positive), while samples with a percentage of inhibition <40% were classified as negative (indeterminate-negative). Sera testing positive for anti-JCV antibodies were diluted in 1:3 dilution steps to determine the anti-JCV antibody titre level.

**Anti-CMV and anti-VZV antibody detection and quantification**

For the anti-CMV antibody status assessment, an ELISA method targeting antigens prepared from the nuclei of CMV-infected fibroblasts (nuclear antigen) was employed as published.18 OD values below 0.2 were considered negative. A standard curve was run on each plate for quality control, and paired samples were studied on the same plate.

A recently published ELISA to determine OD values for highly specific IgG-antibodies against a recombinant VZV glycoprotein E antigen produced in mammalian cells was used to study for anti-VZV antibodies, and paired samples were analysed on the same plate.19 20

**Statistical analysis**

Calculations were performed in GraphPad Prism V.5.0 for Windows (GraphPad Software, San Diego, California, USA). For categorical values, the χ² test or the Fisher’s exact test was applied depending on sample size. Continuous unpaired samples were compared applying the Mann–Whitney test or the Kruskal–Wallis test with Dunn’s Multiple Comparison test where indicated; paired samples were studied applying the Wilcoxon matched-pairs test. To assess differences in the seropositivity rates across equally spaced age groups, the χ² test for trend was used. p Values were based on two-tailed statistical tests and considered significant if <0.05.

**RESULTS**

**Seropositivity for anti-JCV antibodies before and during therapy with NAT**

As shown in table 1, age and gender were similar for patients in the NAT-group, the IFN-subgroups, and the PML patients. While the NAT-group and the IFN2-subgroup had a similar time between sampling, the latter was longer for the IFN1-subgroup and the PML patients compared with the NAT-group (table 1).

The seropositivity rates for anti-JCV antibodies in the 839 patients of the NAT-group were within the previously reported range, and did not change after treatment initiation with NAT.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patient characteristics</th>
<th>NAT-group (t3–t4)</th>
<th>IFN1-subgroup (t1–t3)*</th>
<th>IFN2-subgroup (t1–t2)*</th>
<th>PML</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total n</td>
<td>839</td>
<td>414</td>
<td>170</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>587 (70)</td>
<td>280 (68)</td>
<td>106 (62)</td>
<td>3 (60)</td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>36 (12–63)</td>
<td>37 (16–63)</td>
<td>37 (16–58)</td>
<td>37 (27–44)</td>
<td></td>
</tr>
<tr>
<td>Median Δ months (range)†</td>
<td>12 (1–38)</td>
<td>21 (1–70)</td>
<td>13 (1–59)</td>
<td>25 (18–49)</td>
<td></td>
</tr>
<tr>
<td>Persistent positives n (% of all)</td>
<td>426 (51)</td>
<td>202 (49)</td>
<td>83 (49)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>278 (65)</td>
<td>123 (61)</td>
<td>47 (57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>38 (13–63)</td>
<td>39 (16–63)</td>
<td>38 (16–58)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Δ months (range)†</td>
<td>12 (1–38)</td>
<td>21 (1–70)</td>
<td>12 (1–40)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Persistent negatives n (% of all)</td>
<td>330 (39)</td>
<td>172 (42)</td>
<td>75 (44)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>245 (74)</td>
<td>127 (74)</td>
<td>53 (71)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>35 (12–58)</td>
<td>35 (15–78)</td>
<td>35 (20–54)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Δ months (range)†</td>
<td>12 (1–38)</td>
<td>19 (1–69)</td>
<td>13 (2–59)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seropositers n (% of all)</td>
<td>45 (5)</td>
<td>8 (2)</td>
<td>8 (5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>36 (80)</td>
<td>4 (50)</td>
<td>4 (50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>34 (14–60)</td>
<td>31 (22–45)</td>
<td>39 (28–45)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Δ months (range)†</td>
<td>23 (1–31)</td>
<td>22 (2–46)</td>
<td>20 (3–43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sero-converters n (% of all)</td>
<td>38 (5)</td>
<td>32 (8)</td>
<td>4 (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female n (%)</td>
<td>28 (74)</td>
<td>26 (81)</td>
<td>2 (50)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age (range)</td>
<td>35 (20–53)</td>
<td>35 (18–53)</td>
<td>33 (25–39)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Δ months (range)†</td>
<td>24 (2–37)</td>
<td>25 (1–52)</td>
<td>11 (1–39)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*IFN1- and IFN2-subgroups are subgroups of the NAT-group defined by samples available prior to NAT therapy at t1 and t2. For details see online supplementary efigure S1.
†Δ months=time between first and last sample.
NAT, Natalizumab; PML, progressive multifocal leukoencephalopathy.
(before NAT (t3): 56%, during NAT (t4): 55%; p=0.731). The seropositivity increased with age (p<0.0001), and was higher for men compared with women (t3: women 53%; men: 62%; p=0.018; t4: women 52%; men: 63%; p=0.005).

Interestingly, 5.4% (45/839) of all patients of the NAT-group (table 1), which was 9.6% (45/471) of the positive patients at t3, reverted to negativity at t4 during the median 12 months of therapy with NAT. Compared with the 426 persistent positives (positive at t3 and t4), these seroconverters had lower median nOD values prior to NAT treatment at t3 (0.158 vs 0.479; p<0.0001, figure 1A), and most had been classified as indeterminate-positive at the first time point (91.1% (41/45) vs 23.2% (99/426); p<0.0001). A similar proportion of the negatives at t3 demonstrated seroconversion to a positive status at t4 (10.3% (38/368) of the negative at t3, or 4.5% (38/839) of all patients). Compared with the 330 persistent negatives (negative at t3 and t4), the seroconverters had slightly higher nOD values at t3 (0.085 vs 0.098; p=0.011, figure 1B), and there was a trend for a higher proportion of patients classified as indeterminate-negative (42.1% (16/38) vs 26.7% (88/330); p=0.057). Interestingly, a comparably high proportion (47.3% (18/38) of the seroconverters during NAT therapy increased by nOD>0.2, suggestive of biological, rather than technical change. By contrast, among the patients who converted from a negative to positive status around the cut-off account for the majority of these patients. By within the variability of the ELISA assay, and thus, fluctuations around the cut-off account for the majority of these patients. By contrast, among the patients who converted from a negative to positive status around the cut-off account for the majority of these patients. By contrast, among the patients who converted from a negative to positive status around the cut-off account for the majority of these patients. By contrast, among the patients who converted from a negative to positive status around the cut-off account for the majority of these patients.
include individuals with primary infection, re-exposure to JCV, or a new site of infection due to the spread of the virus; further studies including subclasses of anti-JCV antibodies are warranted to better understand this observation with regard to its potential relevance to the pathogenesis of PML.

In anti-JCV antibody positive patients the median anti-JCV antibody levels declined slightly after the treatment initiation with NAT (figure 2), while they were unchanged during the preceding therapy with IFN. In addition, a decline in anti-VZV antibody levels was noted after start of treatment with NAT, which was greater compared with the decline observed during IFN therapy (figure 4). Our findings in the IFN-treated patients are in line with published literature, reporting stable anti-JCV antibody levels, or slightly declining anti-VZV antibodies over time. By contrast, our data during the NAT therapy is suggestive of a mild suppressive treatment effect on anti-JCV and anti-VZV antibody levels. NAT targets the α4β1 and α4β7, expressed on B and T cells during various stages of development and maturation in a tissue-specific manner. These integrins are considered to be

Figure 1 Changes to anti-JCV antibody status after treatment initiation with natalizumab. (A) Sero-reverters (positive at t3 [prior to NAT]; negative at t4 [after treatment initiation with NAT]) had lower nOD values at t3 compared with persistent positives (positive at t3 and t4).
(B) Seroconverters (negative at t3, positive at t4) had slightly higher nOD values at t3 compared with persistent negatives (negative at t3 and t4).
(C) nOD values shown for all patients negative at t1 [first time point during IFN therapy] who converted to positivity at any time point during the study (t2 [second timepoint during IFN], t3, or t4).
(D) Median ΔnOD was higher in sero-converters during NAT therapy compared with those converting at t2 or t3 during IFN treatment. box: interquartile range; horizontal line: median; whiskers: 5-95 percentile.*p<0.05; **p<0.01; *** p<0.001 (Mann-Whitney or Wilcoxon matched pair test); horizontal interrupted line: upper cut-off point of the ELISA at nOD=0.25.

Figure 2 Changes to anti-JCV nOD values in the NAT-group, the IFN-subgroups, and the PML patients. (A) nOD values slightly decreased in anti-JCV positive patients of the NAT-group, were unchanged during IFN therapy (IFN1-subgroup, the IFN2-subgroup), or increased in the 5 PML patients. (B) All PML patients increased in nOD by nOD>0.151, while only a small proportion of the anti-JCV positive patients showed a similar increase during IFN or NAT therapy.
(C) The median absolute nOD values of the 5 PML patients (black circles and lines) and the NAT-group (grey, depicted as box and whiskers) did not differ at t3, but were higher at time of PML diagnosis (Dx) compared to the values of the NAT-group at t4. box: interquartile range; horizontal line: median; whiskers: 5-95 percentile. **p<0.01; ***p<0.001 (Kruskal-Wallis test with Dunn’s Multiple Comparison Test or Fisher’s exact test).
important for homing and adhesion of leukocytes to their niches. Various groups have reported changes to B cell homeostasis in the peripheral blood during NAT treatment, with higher numbers of immature pre-B cells and memory and marginal zone like B cells being found in the peripheral blood compartment.24–29 Importantly, impaired homing of these cells to their natural niches might be associated with a loss of prosurvival stimuli relevant to the persistence and quality of the antibody response to recall-antigens.30 A suppressive mechanism affecting the humoral memory response, but not the response toward a neoantigen, could potentially explain our findings: increases in nOD after seroconversion in anti-JCV antibody negatives, as well as a mild decline in antibody levels in the antibody positives. Therefore, further studies assessing the humoral memory function might contribute to further elucidate the pathogenesis of PML during therapy with NAT.

By contrast with the findings for anti-JCV and anti-VZV antibodies, anti-CMV antibodies increased slightly during NAT treatment (figure 4). This could potentially be explained by the different natural kinetics of the antibody responses to different viruses, as previously reported22: compared with JCV and VZV, CMV causes a blood-borne persistent infection that induces a strong antiviral antibody response, with increasing titres years after infection,31 32 and higher median anti-CMV antibody levels in the elderly.33 The blood-borne persistent infection with CMV might be associated with a higher frequency of subclinical reactivations, and thus, a different mechanism to maintain the immunological memory response.

For anti-JCV antibody positive patients, the overall downwards trend in antibody levels was associated with a significantly reduced proportion of patients increasing in anti-JCV antibody levels (figure 2). This is of importance, as at time of PML diagnosis, all five Swedish patients with PML showed an upwards trend in anti-JCV antibodies, while anti-VZV and anti-CMV antibodies did not follow these kinetics (figure 3). Therefore, we conclude that the onset of PML can be accompanied by an increase in anti-JCV antibody levels in serum, possibly driven by a new site of infection with a lytic character, and/or the pathogenic transformation of the virus (figure 3). In line with our findings, an increase in anti-JCV antibody levels in serum during the course of PML has been previously observed.34 Frampe et al35 recently reported on nine patients with pre-PML samples studied for anti-JCV antibodies: all nine
had relatively high levels of anti-JCV antibodies (nOD >0.6) before PML diagnosis, and of the four with more than one pre-PML sample, three showed an increase in nOD values over time. In our cohort, while only 2/5 patients had absolute nOD values >0.6, 100% of the patients (with 95% specificity) had mild to moderate increases in nOD compared with a baseline value in the same individual prior to start with therapy (figures 2 and 3). We therefore conclude that the monitoring of anti-JCV antibodies for high levels prior to NAT, or increasing levels during the therapy with NAT (our data), could potentially allow the prediction or earlier diagnosis of PML, at least in a proportion of the anti-JCV positive patients.

There are limitations to our large-scale national study: our cut-off for an increase in nOD values is empirically set based on the changes to anti-JCV antibodies in a cohort of NAT-treated anti-JCV positive patients with a median time between sampling of only 12 months (range 1–38 months), and only five cases of PML, all diagnosed after the first year of therapy. Considering the fact that the anti-JCV antibody positive patients who did not develop PML were sampled only once during the NAT therapy, and the time between sampling was shorter compared with the PML cases, the natural fluctuations of anti-JCV antibody levels not predictive for the development of PML most likely are not entirely reflected in our study. In addition, although the changes observed were highly consistent, and the virus-specificity of the increase in anti-JCV antibodies for the PML cases was supported by anti-VZV and anti-CMV antibodies not changing, the increases were mild, and just above our empirically defined threshold in two of the five PML cases. Therefore, our data should ideally be confirmed in a prospective longitudinal multicentre trial, including a larger number of PML patients, and controls. Such a study might be well worth performing: in combination with high clinical vigilance and regular follow-up imaging, changes to the anti-JCV antibody levels in serum in the antibody positive risk cohort could broaden our armamentarium in the PML risk surveillance of patients treated with NAT. Since the measurement of anti-JCV antibody levels only requires a serum sample that can be taken at the time of a scheduled infusion, further evaluation of this approach to stratify patients for higher or lower risk of PML could be relatively straightforward.

Acknowledgements The analysis for anti-JCV antibodies was sponsored by Biogen Idec. Dr Warnke is supported by an ECTRIMS fellowship stipend, and the KI foundation (2011FoBi1135). Dr Olsson has received grant support for MS research from the Swedish Research Council, EU IP6, Neuropromis and Eurotools, Söderbergs Foundation and Bibbi and Niels Jensens foundation. Dr Bergström is supported by VR-M (grant no 521–2011-3297) and LUA-ALF (grant ALF Gb 145841). Dr Warnke, Dr Fogdell-Hahn and Dr Kieseier received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115303, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. Dr. Kieseier is supported from grants from the German Ministry for Education and Research (BMBF, “German Competence Network Multiple Sclerosis” (KKNMS), Nataлизумаб-Фармаковиژиланстуди, 01G1002). The communicating author highly appreciates the excellent help of Anna Mattsson, Elin Engdahl, Malin Lundkvist, Christina Herrmann, Helga Westerlund, Alexandra Ahlberg, Roger Jungedal, Jenny Link, Izaura Lima Bomfim, Belghis Davoudi, Veronika Bedarova, Lea Mascarel Maric, Agnete Carlsson, Maria Johansson, Ingegerd Löfving Ahnholm, Katharina Fink, Charlotte Dahlé, Anna-Lena Hammar and Benita Zwergbjerg-Wirtgat.

Contributors Study concept and design: CW, TO, SG, JH and AF-H. Acquisition and analysis of data: CW, RR, TB, SG, TP, MS, AR, IK, CH and AF-H. Statistical analysis and CR: Drafting of manuscript: CW and AF-H. Critical revision of the manuscript for important intellectual content: TO, JH and AF-H.

Competing interests Dr Warnke is funded by an ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) fellowship stipend and received travel expenses for attending conferences from Teva Pharma GmbH. Dr Kockum, Dr Bergström, Ms Holmen and Dr Rahbar declare no conflict of interest. Dr Plavina and Dr Subramanyam are employees of Biogen Idec and hold stocks with Biogen Idec. Dr戈尔茨 is an employee of Elan Pharmaceuticals and holds stocks with Elan Pharmaceuticals and Biogen Idec. Dr Kieseier has received personal compensation for activities with Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Sanofi Aventis Pharmaceuticals, Takeda and Teva Neuroscience. Dr Kieseier has research support from Bayer Schering, Biogen Idec, Merck Serono and Teva Neuroscience. Dr Hillert has received unrestricted research support from Biogen Idec, MerckSerono and Bayer Schering. Dr Olsson has received grant support for MS research from the Swedish Research Council, EU IP6, Neuropromis and Eurotools, Söderbergs Foundation and Bibbi and Niels Jensens foundation. Unrestricted grant support has been received from Biogen Idec, Bayer, SanofiAventis and Merck. Lecture fees and/or advisory board consultancies for the same companies. Dr Fogdell-Hahn has received unrestricted research support from Biogen Idec, MerckSerono, and Bayer Schering. The analysis for anti-JCV antibodies was performed and sponsored by Biogen Idec.

Ethics approval Karolinska Institutet regional ethical committee (KI Derm 2006/17, 2006-08-23).

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.

REFERENCES


